Advertisement
Screener

EMERGENT BIOSOLUTIONS INC. (EBS) Other Comprehensive Income (Loss), Net of Tax

2.0 / 5 stars · 47/120 Roast Me

EMERGENT BIOSOLUTIONS INC. Other Comprehensive Income (Loss), Net of Tax

EMERGENT BIOSOLUTIONS INC. (EBS) reported Other Comprehensive Income (Loss), Net of Tax of -$4.10 million for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-07.

Discontinued › Income Statement › Unrealized Gains

us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2019-11-07

  • EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), net of tax for the quarter ending 2019-09-30 was -$4.10M.
  • EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), net of tax for the quarter ending 2019-06-30 was -$500.00K.
  • EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), net of tax for the quarter ending 2019-03-31 was $1.00M, a 150.00% increase year-over-year.
  • EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), net of tax for the quarter ending 2018-12-31 was -$800.00K.
  • EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), net of tax for fiscal 2018 was -$1.80M, a 400.00% decline from fiscal 2017.
  • EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), net of tax for fiscal 2017 was $600.00K.
  • EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), net of tax for fiscal 2016 was -$1.60M.
Period endOther Comprehensive Income (Loss), Net of Tax 3 monthOther Comprehensive Income (Loss), Net of Tax 6 monthOther Comprehensive Income (Loss), Net of Tax 9 monthOther Comprehensive Income (Loss), Net of Tax 12 month
2019-09-30-$4.10M
10-Q · filed 2019-11-07
-$4.60M
derived: sum of 2 quarters · filed 2019-11-07
-$3.60M
10-Q · filed 2019-11-07
-$4.40M
derived: sum of 4 quarters · filed 2019-11-07
2019-06-30-$500.00K
10-Q · filed 2019-08-02
$500.00K
10-Q · filed 2019-08-02
-$300.00K
derived: sum of 3 quarters · filed 2019-08-02
-$500.00K
derived: sum of 4 quarters · filed 2019-11-07
2019-03-31$1.00M
10-Q · filed 2019-05-08
$200.00K
derived: sum of 2 quarters · filed 2019-05-08
$0.00
derived: sum of 3 quarters · filed 2019-11-07
-$1.20M
derived: sum of 4 quarters · filed 2019-11-07
2018-12-31-$800.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22
-$1.00M
derived: sum of 2 quarters · filed 2019-11-07
-$2.20M
derived: sum of 3 quarters · filed 2019-11-07
-$1.80M
10-K · filed 2019-02-22
2018-09-30-$200.00K
10-Q · filed 2019-11-07
-$1.40M
derived: sum of 2 quarters · filed 2019-11-07
-$1.00M
10-Q · filed 2019-11-07
2018-06-30-$1.20M
10-Q · filed 2019-08-02
-$700.00K
10-Q · filed 2019-08-02
2018-03-31$400.00K
10-Q · filed 2019-05-08
2017-12-31$600.00K
10-K · filed 2019-02-22
2016-12-31-$1.60M
10-K · filed 2019-02-22

Similar stocks

Stock NameCountryMarket CapPE Ratio
ENANTA PHARMACEUTICALS INC (ENTA)United States$0.349B-6.72
Larimar Therapeutics, Inc. (LRMR)United States$0.344B-1.83
Vogenx, Inc. (VOGX)United States$0.355B
Benitec Biopharma Inc. (BNTC)United States$0.337B-10.08
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
Evommune, Inc. (EVMN)United States$0.320B-5.10
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
Rezolute, Inc. (RZLT)United States$0.382B-6.45